A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/19 (2006.01) A61P 35/00 (2006.01) A61P 35/04 (2006.01) A61P 37/04 (2006.01) A61P 37/08 (2006.01)
Patent
CA 2596232
Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc. has been inevitable. It is intended to provide a therapeutic method that ensures less side effects but higher efficacy than in conventional therapeutic methods through enhancing of immune strength inherently had by living organism. There is provided an immunopotentiating agent comprising MIP~1.alpha. or its functional derivative as an active ingredient.
Le problème à résoudre dans le cadre de cette invention repose sur le fait que l~immunothérapie n~a pas toujours produit des effets satisfaisants et que le recours à une attaque directe des cellules par des agents anticancéreux, par la radiothérapie, entre autres, s~est avéré inévitable. La présente invention concerne un procédé thérapeutique permettant d~assurer une réduction des effets secondaires tout en obtenant une efficacité supérieure par rapport aux procédés thérapeutiques conventionnels, en renforçant la force immunitaire intrinsèque à l~organisme vivant. Cette invention décrit un agent immunostimulant comprenant, en tant que principe actif, MIP·1.alpha. ou son dérivé fonctionnel.
Kanegasaki Shiro
Tamatani Takuya
Eci Inc.
Effector Cell Institute
Robic
LandOfFree
The use of emip as cancer therapeutics in combination with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The use of emip as cancer therapeutics in combination with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of emip as cancer therapeutics in combination with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1976280